Technology
One capture. A widening set of answers.
The platform takes a single optical reading of a blood sample and interprets it in software. Nothing is added to the sample. Nothing is consumed. The same hardware that ships on day one gains capability through updates rather than through new assays.
The principle
The structure and behaviour of a cell is the data.
Everything a conventional panel throws away is still in the sample at the moment of measurement.
The data VidaLens works from is the cell itself: its shape, its volume, its internal organisation and its optical behaviour. All of that is present in a blood sample at the moment of measurement, and a conventional panel discards nearly all of it in the act of reducing a population of cells to a count.
Conventional hematology reduces a population of cells to counts and chemical proxies, and discards the rest. A cell has shape, volume, internal organisation and optical behaviour, and all of it is present in the sample at the moment of measurement. The platform is built to read that directly.
Why software is the product
Hardware captures once. Everything after that is software.
A new capability is a new model, not a new instrument and not a new assay to validate from scratch.
The optical core is fixed. The models that interpret its output are not. A new capability is a new model against the same capture, which means it deploys as an update rather than as a new instrument, a new consumable or a new assay to validate from scratch.
Built for everyone it serves
Designed and tested across populations.
A condition of the technology being trustworthy, not a feature added afterwards.
VidaLens designs and tests across populations from the start. Blood presents differently across ancestry, age and sex, and a platform validated on a narrow population is a platform built for a narrow population. Working across the full range is treated here as a condition of the technology being trustworthy.
Reliable performance across diverse populations is a condition of the technology being trustworthy, not a feature added afterwards.
Products
Two devices, one optical core.
Both are in development. Neither is cleared by FDA, and neither is available for clinical use.
VidaLens is developing two devices on one optical core. Pulse is the intended first commercial device, built around a fingerstick sample and designed for point-of-care use. Nexus is a second generation intended to extend the same core beyond the complete blood count. Both are in development and neither is cleared.
First commercial device
Reagent-free optical core, fingerstick sample, CBC plus five-part differential, point-of-care ready.
Second generation, in development
Built on the same optical core, extending beyond the complete blood count.
How it differs
A difference of method, not of claim.
Descriptive attributes only. Nothing below compares what either approach finds, or how well it finds it.
The difference between the two approaches is in how the measurement is made, not in any claim about the result. A conventional analyser runs reagent chemistry on a prepared sample; VidaLens is designed to read the sample optically and do the interpretation in software. The table below is limited to that difference.
| Attribute | Conventional CBC analyser | VidaLens (in development) |
|---|---|---|
| Sample | Venous draw, typically into a tube | Fingerstick, by design |
| Reagents | Required | None |
| Per-test consumables | Yes | None, by design |
| Adding a capability | A new assay, developed and validated as such | Intended as a software update against the same capture |
| Regulatory status | Cleared and in routine clinical use | Prototype. Not FDA cleared, not for sale |
Scroll the table sideways to see the VidaLens column.
What we are not claiming
The boundaries of everything above.
Stated here in full. This section links nowhere on purpose.
The platform is at prototype stage. It is not FDA cleared, it is not for sale, and it is not for use in diagnostic procedures.
Nothing on this site is a claim of diagnostic performance.
Questions
Common questions.
Answered at the level the company can currently answer them. Where a fact is not stated here, it is not yet public.
What is VidaLens?
VidaLens is a pre-revenue medical technology company developing a label-free, reagent-free optical platform for blood diagnostics. The platform is designed to take a single optical reading of a blood sample and interpret that reading in software. VidaLens is at prototype stage and is not cleared by FDA.
What stage is VidaLens at?
VidaLens is at prototype stage, described on the roadmap as Phase 0. Sample collection and pre-submission work are ongoing, and the company has stated an intent to file a Q-Sub with FDA. Nothing is available for sale, and nothing is available for clinical use.
Is VidaLens FDA cleared?
No. Neither device is cleared by FDA, neither is for sale, and neither is for use in diagnostic procedures. The regulatory pathway is publicly described as modelled on the Sysmex XW-100 dual 510(k) and CLIA Waiver precedent.
Does the platform use reagents?
No. The optical core is designed to read the sample directly, so nothing is added to the sample and nothing is consumed per reading. That is a description of the measurement method and of the intended design, not a statement about what the platform finds.
What sample is the platform designed to use?
Pulse, the intended first device, is designed around a fingerstick sample rather than a venous draw, with no phlebotomist and no tube. That is a stated design intent for a device in development, not a description of a finished product.
What are Pulse and Nexus?
Pulse is the intended first commercial device: a reagent-free optical core built around a fingerstick sample and designed for point-of-care use. Nexus is a second-generation platform intended to extend the same optical core beyond the complete blood count. Both are in development and neither is cleared by FDA.
How is the platform intended to gain new capability?
Through software. The optical hardware is designed to capture the signal once, and the models that interpret that capture are separate from it. A new capability is intended to be a new model against the same capture, deploying as an update rather than as a new instrument, a new consumable or a new assay validated from scratch.
Who is the platform for today?
Investors, research groups and prospective hospital partners. VidaLens is at prototype stage, so there is no patient-facing product and no clinical availability. This site is written for people evaluating the technology, not for people seeking a test.